July 29, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Memorandum of Understanding ("MOU") between Vilin Bio Med Limited and Ideal Pharma BV

Dear Sir / Madam

This is to inform you that, Vilin Bio Med Limited has signed a Memorandum of Understanding (MOU) with Ideal Pharma BV, Netherlands, to collaborate for distribution of Generic and Branded Medicines with Ideal Pharma's established European Wholesale Distribution Infrastructure.

Further, the information required under the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed herewith as "Annexure-A"

Kindly take the above information on record.

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.07.29 15:06:39 +05'30'

Madhusudhan Yadamakanti Reddy
Managing Directors
DIN: 02874260

Annexure A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated 30th January, 2026.

Sl No	Particulars	Details
	Name(s) of the Parties with whom the Agreement is entered;	Ideal Pharma BV
	Purpose of entering into the Agreement;	The Parties will cooperate on Preferential and long-term basis across the full range of Pharmaceutical and Healthcare products in Europe.
	Shareholding, if any, in the Entity with whom the Agreement is executed;	Nil
	Significant terms of the Agreement (in brief) Special Rights like right to appoint Directors, First Right to share Subscription in case of issuance of Shares, right to restrict any change in Capital Structure etc.	1. The Parties have agreed to collaborate in the areas of distribution of Generic and Branded Medicines across Europe. The allocation of responsibilities is indicative in nature and shall be finalised through Definitive Agreements to be executed between the Parties. 2. The MOU does not confer any Special Rights such as the Right to appoint Directors, Pre-emptive Rights or First Right to subscribe to Shares, Veto Rights over changes in Capital Structure, or any other Shareholder or Management Rights. The Parties shall execute Definitive Agreements, where required, to govern the specific transactions or projects contemplated under the MOU.
	Whether, the said Parties are related to Promoter / Promoter Group / Group Companies in any manner. If yes, nature of relationship	No
	Whether the transaction would fall within Related Party Transactions? If yes, whether the same is done at Arm's Length	No

	In case of issuance of Shares to the Parties, details of Issue Price, Class of Shares issued	Not Applicable
	In case of Loan Agreements, details of Lender / Borrower, Nature of the Loan, Total Amount of Loan granted / taken, Total Amount Outstanding, Date of execution of the Loan Agreement / Sanction Letter, details of the Security provided to the Lenders / by the Borrowers for such Loan or in case Outstanding Loans lent to a Party or borrowed from a Party become material on a cumulative basis;	Not Applicable
	Any other disclosures related to such Agreements, viz., details of Nominee on the Board of Directors of the Listed Entity, Potential Conflict of Interest arising out of such Agreements, etc.	Not Applicable
	In case of termination or amendment of Agreement, Listed Entity shall disclose additional details to the Stock Exchange(s): i. Name of Parties: ii. Nature of the Agreement: iii. Date of Execution: iv. Details of amendment / termination and impact:	Not Applicable